Rocket Pharmaceuticals Inc [NASDAQ: RCKT] slipped around -0.86 points on Tuesday, while shares priced at $5.81 at the close of the session, down -12.89%.
Compared to the average trading volume of 1.57M shares, RCKT reached a trading volume of 7684632 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Rocket Pharmaceuticals Inc [RCKT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RCKT shares is $40.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RCKT stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Rocket Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 12, 2025. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on December 30, 2024, representing the official price target for Rocket Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $29, while Jefferies analysts kept a Buy rating on RCKT stock.
The Average True Range (ATR) for Rocket Pharmaceuticals Inc is set at 0.60 The Price to Book ratio for the last quarter was 1.34, with the Price to Cash per share for the same quarter was set at 3.49.
How has RCKT stock performed recently?
Rocket Pharmaceuticals Inc [RCKT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.89. With this latest performance, RCKT shares dropped by -33.90% in over the last four-week period, additionally sinking by -68.53% over the last 6 months – not to mention a drop of -78.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RCKT stock in for the last two-week period is set at 23.00, with the RSI for the last a single of trading hit 17.91, and the three-weeks RSI is set at 26.62 for Rocket Pharmaceuticals Inc [RCKT]. The present Moving Average for the last 50 days of trading for this stock 9.46, while it was recorded at 7.13 for the last single week of trading, and 15.57 for the last 200 days.
Rocket Pharmaceuticals Inc [RCKT]: Deeper insight into the fundamentals
Rocket Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Earnings analysis for Rocket Pharmaceuticals Inc [RCKT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RCKT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rocket Pharmaceuticals Inc go to 73.89%.
Insider trade positions for Rocket Pharmaceuticals Inc [RCKT]
There are presently around $106.97%, or 110.30%% of RCKT stock, in the hands of institutional investors. The top three institutional holders of RCKT stocks are: RTW INVESTMENTS, LP with ownership of 17.69 million shares, which is approximately 18.8677%. WELLINGTON MANAGEMENT GROUP LLP, holding 9.16 million shares of the stock with an approximate value of $$197.12 million in RCKT stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$133.33 million in RCKT stock with ownership which is approximately 6.6057%.
